This week could bring recommendations for approval throughout the EU for an important immuno-oncology drug, new treatments for mastocytosis and atopic dermatitis, several generics, including the first centrally-approved generic versions of Bristol Myers Squibb’s Baraclude (entecavir), and Johnson & Johnson’s quadruple HIV treatment that combines darunavir, cobicistat, emtricitabine, and tenofovir alafenamide.
The European Medicines Agency’s evaluation committee, the CHMP, is considering for an opinion 13 initial marketing authorization applications (MAAs) at...






